Trials / Recruiting
RecruitingNCT07028281
A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors
A Multicenter, Open-label, Phase II Clinical Study of SHR-4849 Injection Combined With Other Antineoplastic Drugs in Patients With Malignant Solid Tumors
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-4849 injection combined with other antitumor drugs in patients with malignant solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-4849、SHR-1316、SHR-8068、BP102、carboplatin、cisplatin | SHR-4849、SHR-1316、SHR-8068、BP102、carboplatin、cisplatin |
Timeline
- Start date
- 2025-07-08
- Primary completion
- 2028-12-01
- Completion
- 2028-12-01
- First posted
- 2025-06-19
- Last updated
- 2026-03-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07028281. Inclusion in this directory is not an endorsement.